Insider buying last 90 days
No open-market insider purchases were filed for TMO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TMO insider filing, plotted on the chart in Gekko.Open TMO in Gekko
NYSE: TMO
Thermo Fisher Scientific (TMO) Stock Analysis & Forecast
Nov 4 close
$706.16+7.82 (+1.1%)
Gekko Brief
AI summaryNov 4 closeThermo Fisher Scientific shares climbed to a new all-time high of $712.17 this week, with the stock closing at $706.16 after a 1.12% gain on Wednesday, marking a second straight day of advances. The move follows Q3 2026 results showing revenue up 9% to $12.14 billion and adjusted EPS of $6.68, alongside raised 2026 guidance tied to demand from pharma, biotech and AI-enabled precision medicine tools. Argus raised its price target to $780 from $560 while maintaining a Buy rating, citing the company's M&A strategy, facility expansions and new AI-powered product offerings.
The stock trades well above both its 50-day average of $658.67 and 200-day average of $552.49, with the trend remaining supportive. The GekkoIndex sits at 52.5, placing it in the Neutral zone. Price stands 14.5% above Gekko Fair Value of $616.50, a gap that has widened following the recent run to the $712.17 high.
The next earnings date falls on 4 February 2027, outside a typical 20-trading-day holding window. Smart-money data shows no insider, Congress or unusual options activity in the current windows, though one billionaire holder and one trailblazer holder are noted. Seasonality from this point in the calendar has averaged a 3.9% gain over the next 20 trading days across 5 years, rising in 3 of them. Analyst sentiment remains heavily tilted toward Buy, with 17 of 20 firms rating it so and a consensus target of $752.12.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Thermo Fisher Scientific price vs fair value
Close $706.16200-day averageGekko Fair Value $616.50
Thermo Fisher Scientific quick facts
- Market cap
- $261.6B
- P/E ratio
- 36
- Forward P/E
- 25.3
- EPS, TTM
- $18.96
- Revenue, TTM
- $47.35B
- Profit margin
- 14.9%
- Dividend yield
- 0.26%
- Beta
- 0.85
- Volume
- 2.45M avg 2.34M
- 1-year return
- +25.0%
- Typical daily move
- ±3%
- Typical 20-day move
- ±5.4%
- 50-day average
- $658.67
- 200-day average
- $552.49
- Next earnings
- Feb 4 before open
- Shares outstanding
- 370.5M
Thermo Fisher Scientific swing-trade checklist
Thermo Fisher Scientific scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $706.16 is above the 50-day ($658.67) and 200-day ($552.49) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
52.5, Neutral
Reading 52.5 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
14.5% above
Price is 14.5% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 91 days
Next report Feb 4, 2027, 91 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.9% on average
From this point in the calendar, the next 20 trading days averaged +3.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Thermo Fisher Scientific stock chart and price history
Thermo Fisher Scientific closed at $706.16 on Nov 4, 2026, +25.0% over the past year, inside a 52-week range of $435.27 to $712.17.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +7.6%
- 3 months
- +21.7%
- 6 months
- +49.3%
- 1 year
- +25.0%
The full TMO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TMO in Gekko
Follow Thermo Fisher Scientific through every session
Put TMO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TMO in GekkoFree for 7 days. No credit card required.
About Thermo Fisher Scientific
Thermo Fisher Scientific supplies scientific research and healthcare markets with a wide mix of products and services, spanning laboratory reagents and instruments, diagnostic kits, and biopharmaceutical support. Its work touches biological and medical research, drug and vaccine development, and disease detection, with a presence across North America, Europe, Asia-Pacific and other regions. The company is known for brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
The business operates through several segments. One supplies reagents, instruments and consumables used in bioscience, genetic science and bioproduction work. Another provides analytical instruments, software and support for research and clinical laboratories. A diagnostics segment makes immunodiagnostic kits, culture media, specimen handling systems and tissue-typing products used in allergy, asthma, autoimmune and transplant testing. A further segment covers laboratory equipment and pharmaceutical services, including clinical research support. Customers include pharmaceutical, biotechnology, academic, government, healthcare, agricultural, environmental and industrial organizations, reached through direct sales staff, customer service teams, online ordering and outside distributors.
Thermo Fisher Scientific trades on the NYSE under the ticker TMO.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- thermofisher.com
Thermo Fisher Scientific GekkoIndex: the smart money zone
Thermo Fisher Scientific’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.5, in the Neutral zone, up 1 point over five sessions.
52.5Neutral
Up 1 point over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | −0.6% | −1.9% | ||
| Accumulation | 231 | 0.0% | −0.2% | ||
| Neutral (current zone) | 369 | +0.7% | +2.1% | ||
| Distribution | 58 | −1.0% | +0.5% | ||
| Selling | 1 | Too few readings yet | |||
Average TMO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TMO price, zone by zone.Track TMO in Gekko
Is Thermo Fisher Scientific stock overvalued? Gekko Fair Value
Thermo Fisher Scientific trades 14.5% above Gekko Fair Value of $616.50, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Thermo Fisher Scientific shares are worth, recalculated every trading day.
$616.50
Gekko Fair Value, Nov 4, 2026
14.5% Overvalued
At the end of Aug 2026 the price was 9.4% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TMO in Gekko
Thermo Fisher Scientific insider and Congress trading
No open-market insider purchases were filed for Thermo Fisher Scientific, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TMO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TMO, plotted on the chart in Gekko.Open TMO in Gekko
Buybacks
Thermo Fisher Scientific has been buying back its own shares.
- Bought back, quarter ended Jun 27, 2026
- $1.00B
- As a share of market cap
- 0.38%
- Trailing four quarters
- $9.00B
From company filings.
Hedge funds and billionaires quarter ended Sep 30
2of the funds Gekko tracks hold TMO.
2added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Thermo Fisher Scientific earnings: next date and track record
Thermo Fisher Scientific reports on Feb 4, 2027, before the open (91 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 4, 2027
Expected before the open, 91 days away
- EPS estimate
- $7.13
- Revenue estimate
- $12.84B
8 of 8reports beat the EPS estimate
±5.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 21, 2026 AI summary
- What they said
- Thermo Fisher Scientific delivered strong Q3 2026 results with revenue growing 9% to $12.14 billion. Adjusted operating income rose 15% to $2.97 billion, with operating margin expanding 120 basis points to 24.5%. Adjusted EPS grew 15% to $6.68. Growth was driven by pharma/biotech and industrial/applied segments (both high single-digit growth), with notable strength in Pharma Services, electron microscopy, and transplant diagnostics. Multiple new product launches across mass spectrometry, electron microscopy, and diagnostics reinforced innovation momentum.
- Guidance
- Management expressed confidence in delivering an 'excellent 2026,' citing improved end market conditions continuing from Q2 into Q3. No specific revenue or EPS targets were provided in this excerpt, but leadership emphasized strong positioning for long-term value creation.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 21, 2026 | $6.68 est $6.40 | $12.14B est $11.95B | −1.6% |
| Jul 23, 2026 | $6.03 est $5.71 | $11.99B est $11.71B | +7.9% |
| Apr 23, 2026 | $5.44 est $5.27 | $11.01B est $10.86B | −8.6% |
| Jan 29, 2026 | $6.57 est $6.45 | $12.22B est $11.95B | −4.8% |
| Oct 22, 2025 | $5.79 est $5.50 | $11.12B est $10.92B | +2.5% |
| Jul 23, 2025 | $5.36 est $5.23 | $10.86B est $10.68B | +11.1% |
| Apr 23, 2025 | $5.15 est $5.10 | $10.36B est $10.23B | −1.9% |
| Jan 30, 2025 | $6.10 est $5.94 | $11.40B est $11.28B | +5.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Thermo Fisher Scientific stock forecast and analyst price targets
Analysts’ average 12-month price target for Thermo Fisher Scientific is $752.12, +6.5% from the last close, from 20 firms rating the stock in the last 90 days.
$752.12consensus 12-month target, +6.5% from the last close
Now $706.16Avg $752.12
Low $575High $830
Each firm’s latest rating in the last 90 days: 20 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Guggenheim | $740 | +4.8% |
| Nov 2 | Barclays | $775 | +9.7% |
| Oct 30 | Bank of America Securities | $795 | +12.6% |
| Oct 29 | Argus Research | $780 | +10.5% |
| Oct 23 | CMB International Securities | $800 | +13.3% |
+2.1%average 20-day move after past Neutral readings
+3.9%average move over the next 20 trading days in the last 5 years
±3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Thermo Fisher Scientific seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Thermo Fisher Scientific averaged +3.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.7% | 2 of 5 |
| Next 10 trading days | +0.5% | 3 of 5 |
| Next 15 trading days | +3.0% | 3 of 5 |
| Next 20 trading days | +3.9% | 3 of 5 |
| Next 30 trading days | +3.5% | 3 of 5 |
For scale, TMO’s typical 20-trading-day move in either direction is about 5.4%.
Thermo Fisher Scientific market cap and key statistics
Thermo Fisher Scientific’s market cap is $261.6B, with a P/E ratio of 36 and revenue of $47.35B over the last twelve months.
Valuation
- Market cap
- $261.6B
- P/E ratio
- 36
- Forward P/E
- 25.3
- EPS, TTM
- $18.96
- Gekko Fair Value
- $616.50
Trading
- Volume
- 2.45M
- Avg volume, 20 days
- 2.34M
- 52-week high
- $712.17
- 52-week low
- $435.27
- Shares outstanding
- 370.5M
Financials
- Revenue, TTM
- $47.35B
- Profit margin
- 14.9%
- Return on equity
- 13.4%
- Quarterly earnings growth, YoY
- +8.7%
Risk and income
- Beta
- 0.85
- Typical daily move
- ±3%
- Typical 20-day move
- ±5.4%
- Dividend yield
- 0.26%
Thermo Fisher Scientific stock news this week
Coverage of Thermo Fisher Scientific this week reads positive: 9 positive, 5 neutral and 5 negative headlines.
- Thermo Fisher Scientific Inc. stock rises Wednesday, still underperforms marketMarketWatch, Nov 4
- Thermo Fisher Scientific stock hits all-time high at 712.17 USDInvesting.com, Nov 4
- This Insider Has Just Sold Shares In Thermo Fisher ScientificSimply Wall St, Nov 4
- 15,095 Thermo Fisher Scientific Inc. $TMO Shares Sold by Bank Julius Baer & Co. Ltd ZurichDefense World, Nov 4
- Thermo Fisher Scientific Inc. $TMO Shares Newly Bought by Associated Banc CorpDefense World, Nov 4
- Thermo Fisher Scientific Inc. $TMO Stock: BOCHK Asset Management Ltd Lowers PositionDefense World, Nov 3
Thermo Fisher Scientific peers
Thermo Fisher Scientific’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
| BSXBoston Scientific | Neutral | 26.8% below |
A peer links to its own page where one exists.
Thermo Fisher Scientific stock FAQ
What is Thermo Fisher Scientific’s market cap?
Thermo Fisher Scientific’s market cap is $261.6B at the Nov 4, 2026 close of $706.16, with 370.5M shares outstanding. The shares trade on a P/E ratio of 36.
What is the Thermo Fisher Scientific stock forecast?
The consensus analyst 12-month price target for Thermo Fisher Scientific is $752.12, +6.5% from the last close. Of the 20 firms that rated the stock in the last 90 days, 17 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Thermo Fisher Scientific stock overvalued or undervalued?
On Gekko’s estimate Thermo Fisher Scientific is overvalued: the Nov 4, 2026 close of $706.16 is 14.5% above Gekko Fair Value of $616.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Thermo Fisher Scientific report earnings next?
Thermo Fisher Scientific is expected to report on Feb 4, 2027, before the market opens (91 days away). Analysts expect earnings of $7.13 per share on revenue of $12.84B. Thermo Fisher Scientific beat the earnings estimate in 8 of its last 8 reports, moving 5.5% on average across the report.
What is Thermo Fisher Scientific’s 52-week high and low?
Thermo Fisher Scientific’s 52-week high is $712.17 and its 52-week low is $435.27; it closed at $706.16 on Nov 4, 2026, +25.0% over the past year.
Is Thermo Fisher Scientific stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Thermo Fisher Scientific the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.